These criteria included: (1) cytopenia as defined by standard hematologic values, (2) somatic SF3B1 mutation, (3) morphologic dysplasia (with or without RS), (4) bone marrow blasts <5% and peripheral blood blasts <1%, and (5) WHO 2017 criteria for MDS 5q-, MDS/MPN-RS-T, or other MDS/MPN or MPN are not met. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.